Can I read Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial on EtoBox?

Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial by John W. Ostrominski; Muthiah Vaduganathan; Brian L. Claggett; Rudolf A. de Boer; Akshay S. Desai; Dan Dobreanu; Adrian F. Hernandez; Silvio E. Inzucchi; Pardeep S. Jhund; Mikhail Kosiborod; Carolyn S.P. Lam; Anna M. Langkilde; Daniel Lindholm; Felipe A. Martinez; Eileen O'Meara; Magnus Petersson; Sanjiv J. Shah; Jorge Thierer; John J.V. McMurray; Scott D. Solomon is a Medicine article available to read on EtoBox.

What is Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial about?

## Aims This pre‐specified analysis of the DELIVER trial examined whether clinical benefits of dapagliflozin in heart failure (HF) with left ventricular ejection fraction (LVEF) >40% varied by baseline New York Heart Association (NYHA) class and examined the treatment effects on NYHA class over time. ## Methods and results Treatment effects of dapagliflozin by baseline NYHA class II (__n__ = 4713) versus III/IV (__n__ = 1549) were examined on the primary endpoint (cardiovascular death or worsening HF event) and key secondary endpoints. Effects of dapagliflozin on change in NYHA class at 4, 16, and 32 weeks were also evaluated. Higher baseline NYHA class was associated with older age, female sex, greater comorbidity burden, lower LVEF, and higher natriuretic peptide levels. Participants with baseline NYHA class III/IV, as compared with II, were independently more likely to experience the primary endpoint (adjusted hazard ratio [HR] 1.16 [95% confidence interval, 1.02–1.33]) and all‐cause death (adjusted HR 1.22 [1.06–1.40]). Dapagliflozin consistently reduced the risk of the primary endpoint compared with placebo, irrespective of baseline NYHA class (HR 0.81 [0.70–0.94] for NYHA cla

Who reads Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial?

Author

John W. Ostrominski; Muthiah Vaduganathan; Brian L. Claggett; Rudolf A. de Boer; Akshay S. Desai; Dan Dobreanu; Adrian F. Hernandez; Silvio E. Inzucchi; Pardeep S. Jhund; Mikhail Kosiborod; Carolyn S.P. Lam; Anna M. Langkilde; Daniel Lindholm; Felipe A. Martinez; Eileen O'Meara; Magnus Petersson; Sanjiv J. Shah; Jorge Thierer; John J.V. McMurray; Scott D. Solomon

Publisher

Wiley

Published

2022

Language

EN

Field

Medicine (Health Sciences)